News Related to Drug Controller General of India

Related coverage linked through entity extraction aliases.

Zydus Lifesciences Launches Biosimilar Eye Drug, Plans Day-One Semaglutide Generic

Feb 27, 2026

Zydus Lifesciences launched ANYRA, India's first indigenous Aflibercept biosimilar for retinal conditions, and secured approval for a March 2026 day-one launch of generic semaglutide for diabetes and obesity treatment.

Zydus Lifesciences Launches Semaglutide, Aflibercept Biosimilar; USFDA Clears Ahmedabad Plant

Feb 26, 2026

Zydus Lifesciences plans to launch Semaglutide injection in India after patent expiry and introduced ANYRA, India's first indigenous Aflibercept biosimilar. The USFDA cleared the company's Ahmedabad injectable facility with zero observations.